舒利迭治疗气道炎症稳定期慢性阻塞性肺疾病患者的效果观察

目的观察舒利迭（沙美特罗/氟替卡松吸入剂）对中重度稳定期慢性阻塞性肺疾病（COPD）气道炎症的临床疗效。方法选取100例稳定期中重度COPD患者随机分为治疗组（50例）和对照组（50例）。治疗组又分为治疗1组28例（嗜酸粒细胞升高型）、治疗2组22例（非嗜酸粒细胞升高型）采用舒利迭治疗,疗程为6个月。对照组采用万托林联合茶碱缓释片进行治疗,疗程为6个月。所有患者治疗前后测定1 s用力呼气容积（FEV1）、用力肺活量（FVC）占预计值的百分比、FEV1/FVC。结果治疗组及对照组治疗前后肺功能FVC占预计值的百分比、FEV1、FEV1/FVC有所改善,差异有统计学意义（P〈0.05）。治疗组显效率及总有效率分别为70%、98%,对照组显效率及总有效率分别为48%、84%。治疗组显效率及总有效率与对照组比较差异均有统计学意义（χ2=5.0021,P=0.0253;χ2=4.3956,P=0.0360）。治疗1组显效率为82.14%,治疗2组显效率为54.55%,治疗1组显效率明显高于治疗2组（χ2=4.4682,P=0.0345）。结论舒利迭吸入剂治疗COPD是有效和安全的,舒利迭吸入剂治疗嗜酸粒细胞升高型COPD的疗效比非嗜酸粒细胞升高型更高。

Clinical observation of the efficacy of Seretide in the treatment of stable chronic obstructive pulmonary disease with airway inflammation phenotype

Objective To investigate the clinical efficacy of Seretide in the treatment of stable chronic obstructive pul monary disease（COPD） with airway inflammation phenotype.Methods 100 patients with stable COPD enrolled in the study were randomly divided into treatment group（50 cases） and control group（50 cases）.Treatment group was divid ed into treatment group 1（eosinophils rise type） and treatment group 2（non-eosinophils rise type）.The treatment group was treated with Seretide for 6 months.The control group was treated with Ventolin combined with Theophylline Sus tained Release Tablets for 6 months.All the patients were detected the level of FVC,FEV1 and FEV1/FVC before and after treatment.Results The markedly effective rate and total effective rate of treatment group were 70% and 98% re spectively.The markedly effective rate and total effective rate of control group were 48% and 84% respectively.The markedly effective rate and total effective rate of treatment group were significant those of control group（χ2=5.0021,P = 0.0253;χ2=4.3956,P = 0.0360）.The markedly effective rate of treatment group 1 was 82.14%.The markedly effec tive rate of treatment group 2 was 54.55%.The markedly effective rate of treatment group 1 was significant that of treatment group 2（χ2=4.4682,P = 0.0345）.Conclusion Seretide is effective and safety in the treatment of COPD especially with eosinophils rise type.